Trial · NCT07428369
Registered outcomes74
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
41 to 60 of 74
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Time to definitive deterioration in GHS per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in physical functioning per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in role functioning per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in pain per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in fatigue per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in disease symptoms per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in treatment side effects per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in body image per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in future perspective per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Time to definitive deterioration in EQ-5D-5L VAS | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in GHS per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in physical functioning per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in role functioning per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in pain per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in fatigue per EORTC QLQ-C30 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in disease symptoms per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in treatment side effects per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in body image per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in future perspective per EORTC QLQ-MY20 | Up to 5 years | Phase 3 |
| Secondary | Time to first improvement in EQ-5D-5L VAS | Up to 5 years | Phase 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07428369/registered?page=3